The role of vasculogenesis as opposed to angiogenesis in tumor formation has been little explored genetically. Endothelial cells that lack the MEK kinase MEKK3 cannot form vessels. In this study, we employed mice with hematopoietic deletions of the Mekk3 gene to evaluate the importance of vasculogenesis in the formation of Ewing's sarcoma tumors. 
Introduction
New blood vessel formation is critical for tumor growth and metastasis (1) . Endothelial cells play an essential role in this process (2) (3) (4) (5) . We previously showed that in addition to angiogenesis, the migration of bone marrow (BM) cells into the Ewing's sarcoma tumor and their subsequent differentiation into endothelial cells and pericytes (vasculogenesis) contributes to the growth of Ewing's sarcoma (6, 7) . It is well established that inhibiting angiogenesis suppresses tumor growth (8, 9) . However, the consequences of blocking vasculogenesis are unclear. Evaluating the importance of BM cells and vasculogenesis to tumor growth requires an in vivo model in which vasculogenesis is selectively blocked but local angiogenesis can occur. Mitogen-activated protein kinases are common mediators in the signal transduction pathways from membrane to nucleus. These kinases sequentially activate the downstream kinases and relay signals from extracellular agonists to the designated targets. Mekk3 is a Ser/Thr protein kinase of the mitogen-activated protein kinase kinase kinase gene family (10, 11) . Mekk3 is involved in early embryonic cardiovascular and blood vessel development. Deletion of Mekk3 is embryonically lethal at embryonic day (E) 9.5 (12) . The Mekk3-deficient yolk sacs have few or no vessels, indicating that this gene plays an essential role in embryonic blood vessel formation. Moreover, cells that lack Mekk3 do not form normal vessels.
To evaluate the importance of vasculogenesis in the growth and development of Ewing's sarcoma, we used Mekk3-deleted BM cells from Mekk3
Δflox/− conditional knockout mice as the donor cells to reconstitute irradiated Mekk3 +/+ nude mice before tumor injection. Our rationale was that Mekk3-deleted (Mekk3 Δflox/− ) BM cells cannot participate in vasculogenesis, yielding a model in which vasculogenesis is blocked in the experimental group but angiogenesis in both the experiment and control groups is equal. If vasculogenesis is critical, tumor growth in the Mekk3
Δflox/− BM-transplanted mice will be smaller compared with tumors from Mekk3 Δflox/+ BM-transplanted mice. Here, we show that Mekk3 Δflox/− BM cells do not participate in tumor vessel formation and that tumor growth is significantly impaired when vasculogenesis is inhibited.
Materials and Methods
Mice Tie2-GFP-Mekk3 +/− mice. Tie2-GFP mice express green fluorescent protein (GFP) under the direction of the endothelial-specific receptor tyrosine kinase (Tek, formerly, Tie2) promoter (13) . Tie2-GFP mice were crossed with Mekk3 +/− mice (12) to create Tie2-GFP-Mekk3 +/− mice. Male and female
Tie2-GFP-Mekk3
+/− mice were set up for time mating to get Tie2-GFP-Mekk3 +/− or Tie2-GFP-Mekk3 −/− day 9.5 embryos. 
PCR Analysis for Mekk3 Genotypes
Genomic DNA from 7-day-old mice tails or BM from donor and recipient mice were isolated and amplified by PCR. The PCR primers used were as follows: P1 (5′-TCGCAGCG-CATCGCCTTC-3′), P2 (5′-ATGTGAAGCTTGGGGATTTTG-3′), P3 (5′-TGGTTAGACTCACTGGTCAGAGAC-3′), and P4 (5′-TTGTGCATCGGGACATCA-3′). Primer combination P1, P2, and P3 yields amplified fragments of 1,000 bp (Mekk3 floxed), 900 bp (Mekk3 wild-type), and 830 bp (Mekk3 knockout). Primer combination P3 and P4 yields amplified fragments of 1,500 bp (Mekk3 floxed), 1,300 bp (Mekk3 wild-type), and 650 bp (Mekk3 Δfloxed), which represents the deleted allele following tamoxifen treatment. Two separate PCR assays are necessary because one assay cannot detect all four alleles. (6, 7, 18) . 3LL cells (10 5 in 0.1 mL) were injected into the right and left flanks in Mekk3
Matrigel Plug Assay
Δflox/+ Cre-ER-R26R and
Mekk3
Δflox/− Cre-ER-R26R mice from the same litter. Cre-ER-R26R mice are LacZ + . These mice were treated with 2 mg of tamoxifen every 48 h for 14 d to achieve deletion of the floxed Mekk3. BM from Mekk3
Δflox/+ and Mekk3
Δflox/− mice were obtained by flushing the femur and tibia with PBS containing 5% fetal calf serum. Freshly isolated BM cells (5 × 10 6 in 100 μL PBS) were injected into the lateral tail vein of 6-wk-old female nude mice that had been irradiated with 8.0 Gy using an external cesium source ( , in which a is the longer diameter and b is the shorter diameter. The chimeric mice were euthanized 3 wk after tumor cell injection. Tumor tissue was analyzed by immunohistochemistry.
Immunohistochemistry and LacZ Staining
Tumor specimens from Mekk3 Δflox/+ and Mekk3 Δflox/− BMtransplanted mice were fixed and cryoprotected in sucrose (35%) overnight, embedded in Tissue-Tek optimum cutting temperature compound, and frozen. LacZ staining was done (19) (20) (21) . Immunohistochemistry using anti-PECAM-1/CD31 antibody (clone MEC13.3; Pharmingen) or anti-desmin (Abcam) on LacZ-stained tissues was performed followed by counterstaining with nuclear fast red (17, 22) . The MVD and mural cell density was determined by averaging the number of CD31 or desmin and LacZ double-positive cells in five random high-power microscopic fields from different tumors.
Expression Plasmids and Transfection siRNA expression vector pSilencer2.1-U6 hygro was purchased from Ambion. siRNA-expressing plasmids targeting human Mekk3 mRNA GTGCAGAAAATTCCTTGTC (23) were annealed at 90°C for 3 min, cooled to 37°C, and incubated for 1 h. The annealed dsDNA oligonucleotides were ligated between BamHI and HindIII sites on the pSilencer2.1-U6 hygro vector. The control vector (si-) was constructed by inserting a sequence that expresses an siRNA with limited homology to sequences in the human and mouse genomes. Transfection of TC71 cells was performed with Lipofectamine 2000 (Invitrogen/Life Technologies). Transfected clones were selected in 400 μg/mL hygromycin B (Invitrogen/Life Technologies). Human Mekk3 expression in the stable clones was quantified by Western blot.
In vivo Experiments Using TC71/Mekk3 si-transfected Clones TC71, TC71/si-control, TC71/Mekk3 si-clone 8, or TC71/ Mekk3 si-clone 10 cells (2 × 10 6 ) were injected s.c. into four groups of nude mice. Tumor growth was quantified every other day. All the tumors were harvested on day 27 and frozen sections were stained using rat anti-mouse CD31 (primary antibody) and goat anti-rat Texas red (secondary antibody). Hoechst 33342 (1:10,000 in PBS) was used for nuclear staining. The MVD was determined by averaging the number of CD31 + cells in five random high-power microscopic fields. Apoptotic cells were quantified using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling.
Results
Mekk3 deficiency inhibits the formation of normal vessel structures. Endothelial cells from Tie2-GFP-Mekk3 +/− and Tie2-GFP-Mekk3 −/− E9.5 yolk sacs were isolated and injected with Matrigel s.c. into nude mice. Vessel formation was assessed after 2 weeks. Mekk3 +/− endothelial cells formed (Fig. 2C) . This Mekk3
Δflox/− mouse model, however, could not be used to assess the importance of vasculogenesis in tumor vessel development because both angiogenesis and vasculogenesis are inhibited. Furthermore, no assessment could be performed with regard to Ewing's sarcoma, as human tumor cells will not grow in immunocompetent mice. Deletion of Mekk3 in BM cells inhibits vasculogenesis and tumor growth. We showed that Mekk3-deficient cells do not form blood vessels and that Mekk3-deficient mice do not support tumor growth. We next used our previously described Ewing's sarcoma transplant model (6) to selectively inhibit vasculogenesis to determine the importance of BM cells in the formation of tumor blood vessels. Recipient nude Δflox/+ BM cells (Fig. 4A and C) . The tumors from the Mekk3
Δflox/− BM-transplanted mice remained small and stable over 17 to 21 days, and seemed to be less vascular in addition to being smaller ( Fig. 4B and D) . Because the BM cells from the donor mice were LacZ + , β-gal staining was used to distinguish cells of donor origin from cells of the host. Colocalization of LacZ and CD31 on tumor vessels was seen in tumors excised from the Mekk3 Δflox/+ BM-transplanted mice (Fig. 5A) . Whereas Lac Z + cells were visualized within the tumor in the Mekk3 Δflox/− BM-transplanted mice, very few of these cells colocalized with the CD31 + cells (Fig. 5A) . Quantification of double-positive LacZ and CD31 cells confirmed that BM cell contribution to tumor vessel formation was impaired following deletion of Mekk3 (Fig. 5A ). These data indicate that whereas the Mekk3-deficient BM cells were able to migrate to the tumor area, their contribution to tumor vessel formation was minimal.
To confirm that angiogenesis was at a similar level in Mekk3
Δflox/+ and Mekk3 Δflox/− BM-transplanted mice, we quantified the number CD31 + /LacZ − vessels in the tumors.
CD31
+ /LacZ − represent tumor vessels with no BM-derived cells and thus can be used as a way to quantify local angiogenesis. There was no difference in the number of CD31 + /LacZ − vessels (Fig. 5B) . These data indicate that the angiogenesis process was similar in the two groups, confirming that the inhibition in tumor growth was secondary to the defect in vasculogenesis. Deletion of Mekk3 inhibits the contribution of BMderived mural cells/pericytes to Ewing's sarcoma vasculature. Interaction between endothelial cells and mural cells/ pericytes plays an important role in vascular formation (24) . We showed that BM-derived mural cells/pericytes contribute to Ewing's sarcoma vessel development (7, 25 pericytes marker) allowed us to quantify BM-derived mural cells/pericytes in tumor vessels and assess whether deleting Mekk3 affected the ability of BM-derived mural cells/ pericytes to contribute to the tumor vascular structure (Fig. 5C ). The quantification of double-positive cells in the tumors from control Mekk3 Δflox/+ BM-transplanted mice (Fig. 5C ) confirmed our previous findings that BM-derived mural cells/pericytes contribute to tumor vessel formation (7, 25) . Deletion of Mekk3 inhibited this process. Very few BM-derived mural cells/pericytes were detected in the tumor vessels from the Mekk3 Δflox/− BM-transplanted mice (Fig. 5C ).
By contrast, macrophage marker F4-80 staining showed no difference between the tumors from mice transplanted with Mekk3 Δflox/− versus Mekk3 Δflox/+ BM cells (data not shown), indicating that the migration and differentiation of myeloid cells was not impaired following deletion of Mekk3. Effect of downregulating Mekk3 in TC71 cells on tumor growth and tumor vessel formation. We have shown that deletion of Mekk3 in BM cells impairs their ability to participate in tumor vessel expansion, resulting in decreased tumor vascular density and mural cells/pericytes coverage. To determine whether tumor cell expression of Mekk3 is required for tumor-induced vessel expansion, Mekk3 in TC71 cells was knocked down using siRNA. Two stable clones were isolated (TC71 clone 8 and TC71 clone 10; Fig. 6A ).
The downregulation of Mekk3 in the TC71 cells had no effect on the ability of these cells to form tumors or stimulate neovascularization. Tumor growth and MVD were similar to the control-transfected cells (Fig. 6B and C) . Tumors were harvested on day 25 to confirm that the Mekk3 downregulation had been maintained (Fig. 6D) .
Discussion
Tumor vessels are formed through at least two different processes: angiogenesis (2, 4, 26) , defined as endothelial cell proliferation from the preexisting vasculature, and vasculogenesis (2, 3, 27) , defined as the recruitment of BM-derived precursors into the tumor area with subsequent differentiation into endothelial cells. The contribution of vasculogenesis varies considerably depending on the tumor type. We have shown that vasculogenesis, in addition to angiogenesis, contributes to the expansion of the Ewing's tumor vascular network with 10% of the vessels containing BM-derived as opposed to locally derived cells (6, 7, 28) . Using a transplant mouse model with GFP + BM cells, we showed that both locally derived and BM-derived cells make up the tumor vessel wall and the surrounding pericyte population (7, 28) . Our previous studies (6, 7, 28) support the concept that BM cells contribute to the endothelial and peri-endothelial components that form the Ewing's tumor vasculature. Inhibiting BM cell chemotaxis into the tumor area resulted in the formation of significantly smaller and less vascular tumors (28) . Furthermore, stimulating the migration of BM cells into vascular endothelial growth factor (VEGF)-inhibited Ewing's tumors in vivo enhanced the neovasculature development and rescued tumor growth (29) . Taken together, these data indicated that the vasculogenesis process is vital in the formation of tumor vessels.
Recent studies have questioned the importance of vasculogenesis to tumor development and growth (20) . Proving that vasculogenesis is a critical process in tumor vessel expansion requires a model in which angiogenesis is intact but vasculogenesis is impaired. In the study presented here, we elected to take advantage of the recent finding that the Mekk3 gene is required for blood vessel development (12 
Mekk3
Δflox/− BM-transplanted mice remained small for over 2 weeks (Fig. 4A and C) . These tumors were less vascular with a significant decrease in MVD and pericyte coverage (Fig. 5) (Fig. 5) . These data suggest that the Mekk3
Δflox/− BM cells were able to migrate to the tumor but unable to participate in vessel formation. This resulted in few BM-derived tumor vessels, confirming the selective inhibition of vasculogenesis. The vessels that were present were derived from the host cells in the surrounding tumor area as they were LacZ − . Our data show for the first time that selectively inhibiting vasculogenesis severely compromised tumor growth. The transplant model used to selectively inhibit BM cell participation in tumor vessel formation required wholebody irradiation. Radiation has been shown to inhibit local angiogenesis to some degree (30 (Fig. 4) . If anything, this shows that vasculogenesis may provide a mechanism for tumor cells to circumvent the negative effect of radiation on angiogenesis, thereby rescuing tumor growth. Our studies indicate that tumor vessel expansion and tumor growth are compromised when BM cells are unable to participate in tumor vascular formation. Altering Mekk3 expression in the TC71 tumor cells had no effect on tumor growth. This is not surprising because altering the status of Mekk3 in tumor cells does not affect VEGF production or the ability of cells in the microenvironment to form vessel (31) . Both the local endothelial cells and the BM cells in this model are Mekk3 +/+ and can therefore participate in tumor vessel formation. These data indicate that the status of Mekk3 in the tumor cell itself is of no consequence to the development of the tumor vasculature.
Others have shown that the growth of Mekk3 deficient tumor-like embryonic stem cells was similar to Mekk3 +/+ embryonic stem cells (31) . MVD was also not affected. This supports our findings that the status of Mekk3 in tumor cells does not affect tumor-induced vessel formation. However, this study did not examine whether Mekk3 deletion in the microenvironment affected tumor growth or tumor vessel formation. Our current study examined both.
In summary, we have shown that MEKK3 plays a key role in the ability of BM stem cells to participate in the formation of tumor vessels, which subsequently significantly affect tumor growth. We also showed that MEKK3 may control critical signaling pathways that are involved in pericyte differentiation and interaction with the vascular endothelium. Finally, we showed for the first time that vasculogenesis and BM cells not only contribute to, but play a critical role in, the development and the expansion of the tumor vascular network that supports the growth of Ewing's tumors. The importance of BM-derived vasculogenesis has also been shown in other tumor models (32, 33) . Inhibiting this process suppresses the ability of Ewing's sarcoma cells to grow. These are important new findings particularly for Ewing's sarcoma, as cure rates have remained stagnant for >20 years. In addition, the long-term effects associated with intensive chemotherapy and radiation underscores the need for more targeted approaches. Targeting the vasculogenesis process may therefore offer novel therapeutic opportunities.
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